- Unilife (UNIS) is flat AH following the release of FQ1 results.
- CEO Alan Shortall says the $3.2M of revenue the company recorded for the period marks "an inflection point." "From here, I expect the slope to be significant," Shortall adds. (PR)
- The shares rallied 9.5% during the regular session after the company announced a supply agreement with MedImmune under which UNIS "will supply customized devices from its platform of ReadyToGo wearable injectors."
- Although UNIS said it would "generate revenue starting in Q1," other financial terms weren't disclosed. (PR)